EYPT

EyePoint's stock has been influenced by financial performance and clinical trial advancements. In Q1 2026, the company missed EPS and revenue forecasts due to the completion of deferred revenue recognition from a previous YUTIQ product rights licensing agreement. The company announced Q4 and full-year 2025 financial results, with a decrease in net revenue and an increase in operating expenses. EyePoint has maintained investor interest through the continued progression of DURAVYU in late-stage clinical trials for wet AMD and DME. As of March 31, 2026, EyePoint had $223 million in cash, expected to fund operations into Q4 2027. Over the past year, EYPT's stock price has increased significantly, but it has underperformed the S&P 500 in the last three months.